Blue Water Biotech Acquires Proteomedix As Part Of Transformation To Commercial Stage Oncology Company; Announces Name Change To Onconetix™
Acquiring Company
Blue Water Biotech
Acquired Company
Proteomedix AG
Cincinnati
SchlierenBiotechnology ResearchBiotechnology ResearchDescription
Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the “Transaction”), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer.
Quick answer
Blue Water Biotech is acquiring Proteomedix AG, announced December 18, 2023. Blue Water Biotech is based in Cincinnati, Ohio, United States.
- How much did Blue Water Biotech pay for Proteomedix AG?
- The deal value was not disclosed.
- What does Blue Water Biotech do?
- Blue Water Biotech Inc. (Nasdaq: BWV) is a biopharmaceutical company focused on developing transformational therapies to address significant health challenges globally.
- Where are Blue Water Biotech and Proteomedix AG based?
- Blue Water Biotech is based in Cincinnati, Ohio, United States. Proteomedix AG is based in Schlieren, Zurich, Switzerland.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology Research and Biotechnology Research
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp (January 25, 2024)
- Pressure BioSciences Announces Closing of Uncle Bud’s Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales (January 22, 2024)
- Parse Biosciences Acquires Biomage (January 16, 2024)
- Pressure BioSciences Signs Definitive Agreement to Acquire Uncle Bud’s, Forward Integrating PBIO’s UltraShear Platform into Multiple Markets (January 11, 2024)
- Sanreno Therapeutics Announces Acquisition By Novartis In Pivotal Transaction To Bring Forward Transformative Therapeutics In Kidney Disease (January 5, 2024)
- Roche Completes Acquisition Of Telavant From Roivant, Including Rights To Novel Tl1A Directed Antibody (Rvt-3101) For The Treatment Of Inflammatory Bowel Disease (December 14, 2023)
Who to call at Blue Water Biotech, and when
When Blue Water Biotech changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Blue Water Biotech raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Blue Water Biotech, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Blue Water Biotech. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Blue Water Biotech makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Proteomedix AG?
Proteomedix AG was acquired by Blue Water Biotech, based in Cincinnati. The deal was reported on December 18, 2023. Blue Water Biotech Inc. (Nasdaq: BWV) is a biopharmaceutical company focused on developing transformational therapies to address significant health challenges globally. Blue Water Biotech is privately held and operates in Biotechnology Research.
When did Blue Water Biotech acquire Proteomedix AG?
Blue Water Biotech's acquisition of Proteomedix AG was reported on December 18, 2023. Blue Water Biotech, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Proteomedix AG do?
Proteomedix enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies. It is privately held, operating in Biotechnology Research, and is based in Schlieren.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.